Valuation: Biodesix, Inc.

Market Cap 301M 262M 248M 226M 422M 28.86B 424M 2.96B 1.14B 14.67B 1.13B 1.11B 46.95B P/E 2026 *
-10.8x
P/E 2027 * -17.3x
Enterprise Value 301M 262M 248M 226M 422M 28.86B 424M 2.96B 1.14B 14.67B 1.13B 1.11B 46.95B EV / Sales 2026 *
2.69x
EV / Sales 2027 * 2.24x
Free-Float
55%
Yield 2026 *
-
Yield 2027 * -
1 day+0.88%
1 week+10.64%
Current month+9.36%
1 month+23.91%
3 months+89.29%
6 months+73.66%
Current year+323.68%
1 week 25.74
Extreme 25.7445
29.42
1 month 21.91
Extreme 21.91
31.31
Current year 5.26
Extreme 5.26
31.31
1 year 5.26
Extreme 5.26
31.31
3 years 3.44
Extreme 3.436
44.2
5 years 3.44
Extreme 3.436
183.8
10 years 3.44
Extreme 3.436
639.8
Manager TitleAgeSince
Chief Executive Officer 54 2019-12-31
Director of Finance/CFO 46 2017-03-31
Chief Tech/Sci/R&D Officer - 2015-12-31
Director TitleAgeSince
Chairman 79 2020-09-13
Director/Board Member 53 2011-12-31
Director/Board Member 59 2020-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/26 Buy 15,000 0.1422%
8/11/26 Buy 13,700 0.1298%
6/30/26 Exercice

Chairman

2,722 0.0340%
Change 5-day change 1-year change 3-year change Capi.($)
+0.88%+10.64%+363.93%-3.32% 301M
+6.07%+12.32%+108.81%+617.41% 49.78B
-0.55%+0.51%+17.75%+60.04% 26.32B
+0.41%+0.62%-12.68%-36.75% 6.89B
+2.64%+4.71%+3.43%+177.59% 5.96B
+1.53%+0.26%+17.71%+64.80% 3.3B
+7.73%+25.00%-17.96%+2,530.33% 2.91B
+5.02%+12.95%+145.25%+52.06% 2.43B
+14.83%+2.34%+37.68%+46.52% 2.26B
0.00%+1.95%-14.64%-54.60% 1.85B
Average +3.86%+4.66%+64.93%+345.41% 10.2B
Weighted average by Cap. +3.72%+3.62%+62.20%+400.17%

Financials

2026 *2027 *
Net sales 112M 97.52M 92.29M 83.85M 157M 10.72B 157M 1.1B 425M 5.45B 421M 411M 17.44B 135M 117M 111M 101M 188M 12.89B 189M 1.32B 511M 6.55B 506M 494M 20.98B
Net income -27.54M -23.99M -22.71M -20.63M -38.54M -2.64B -38.73M -270M -105M -1.34B -103M -101M -4.29B -19.47M -16.96M -16.05M -14.58M -27.25M -1.86B -27.38M -191M -73.93M -948M -73.15M -71.52M -3.03B
Net Debt - -
Logo Biodesix, Inc.
Biodesix, Inc. is a diagnostic solutions company. The Company's business includes Biodesix Lung Diagnostic Testing and Biodesix Development Services. Its Biodesix Lung Diagnostic Testing provides lung diagnostic testing services for healthcare providers through five blood-based tests. Its Biodesix Development Services supports global biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that enable the development of diagnostic tests, tools, and therapeutics. The Company offers Nodify Lung tests and IQLung tests that assess cancer risk and provide treatment guidance following a lung cancer diagnosis. The Nodify Lung tests include Nodify CDT and Nodify XL2 tests, which evaluate the risk of lung cancer in lung nodules. The GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests are used in the diagnosis of lung cancer to detect tumor mutations and assess the patient’s immune system status.
Employees
334
Date Price Change Volume
26-09-17 US$28.81 +0.88% 60,835
26-09-16 US$28.56 +3.10% 100,566
26-09-15 US$27.70 +1.09% 69,520
26-09-14 US$27.40 +1.61% 54,989
26-09-11 US$26.97 +3.55% 47,060
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
28.56USD
Average target price
34.00USD
Spread / Average Target
+19.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDSX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!